2021 PRESENTING COMPANIES
October 7, 2021
AsclepiX Therapeutics, Inc. is a clinical stage biopharmaceutical company using computational biology to identify potent peptide regulators of vascular homeostasis that is disrupted in ocular and oncologic diseases. The novel clinical candidate peptides discovered by AsclepiX tap into these naturally existing self-regulating mechanisms, evolved over millions of years, that the body uses to maintain homeostasis and thus restore and maintain health. AXT107, an investigational product candidate and the lead clinical candidate, has a unique mechanism of action that targets two clinically proven pathways of diseases of the retina. For more information, please visit: www.asclepix.com
Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside’s proprietary SCS Microinjector® targets the suprachoroidal space (SCS®) and offers unique access to the macula, retina and choroid where sight-threatening disease often occurs. The Company’s SCS injection platform is an inherently flexible, in-office, non-surgical procedure, intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications. For more information, please visit www.clearsidebio.com.
An Ophthalmic Home Diagnostic Services company, Notal Vision extends retina disease management from the clinic to the home to improve vision outcomes, reduce patient burden, and address healthcare costs. With a proven approach to the home testing experience, patient-operated devices, and real-time AI-enabled data interpretation, we are advancing eyecare through precision medicine. It is this unique assembly of core competencies that enables us to deliver personalized eyecare to patients. Retinal diseases that present with acute onset, unpredictable activity, and varying drug response pose challenges to healthcare and create addressable unmet needs. Home Diagnostic Services support the promise of enabling patients to retain functional vision throughout their years-long disease journey.
Ocuphire is a clinical-stage ophthalmic company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire’s pipeline currently includes two small-molecule product candidates, Nyxol and APX3330, targeting front and back of the eye indications respectively. APX3330 is a twice-a-day oral tablet designed to target multiple pathways relevant to retinal diseases including diabetic retinopathy (DR) and diabetic macular edema (DME). APX3330 had been studied in six Phase 1 and five Phase 2 trials totaling over 340 patients for inflammatory and oncology indications, and demonstrated promising evidence of tolerability, pharmacokinetics, durability, and target engagement. Ocuphire is currently enrolling patients in Phase 2 trial for APX3330 for treatment of patients with DR, including moderately severe non-proliferative DR and mild proliferative DR, as well as patients with DME without loss of central vision. Future trials will explore APX3330 for retinal indications including wet age-related macular degeneration, and geographic atrophy.